Citigroup’s Cardiff Oncology CRDF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $65.2K | Buy |
40,266
+38,863
| +2,770% | +$79.8K | ﹤0.01% | 4428 |
|
|
2025
Q4 | $3.94K | Sell |
1,403
-219
| -14% | -$508 | ﹤0.01% | 5306 |
|
|
2025
Q3 | $3.34K | Sell |
1,622
-19,867
| -92% | -$54.9K | ﹤0.01% | 5351 |
|
|
2025
Q2 | $67.7K | Sell |
21,489
-19,380
| -47% | -$59.1K | ﹤0.01% | 4613 |
|
|
2025
Q1 | $128K | Buy |
40,869
+8,897
| +28% | +$35.2K | ﹤0.01% | 4454 |
|
|
2024
Q4 | $139K | Buy |
31,972
+3,485
| +12% | +$10.9K | ﹤0.01% | 4654 |
|
|
2024
Q3 | $76.1K | Buy |
28,487
+19,798
| +228% | +$46.8K | ﹤0.01% | 4884 |
|
|
2024
Q2 | $19.3K | Sell |
8,689
-74,425
| -90% | -$280K | ﹤0.01% | 5012 |
|
|
2024
Q1 | $444K | Buy |
+83,114
| New | +$221K | ﹤0.01% | 3656 |
|
|
2023
Q2 | – | Sell |
-651,161
| Closed | -$1.07M | – | 5584 |
|
|
2023
Q1 | $1.07M | Buy |
651,161
+651,061
| +651,061% | +$1.12M | ﹤0.01% | 2487 |
|
|
2022
Q4 | $140 | Buy |
+100
| New | +$143 | ﹤0.01% | 5623 |
|
|
2022
Q3 | – | Sell |
-379
| Closed | -$1K | – | 5892 |
|
|
2022
Q2 | $1K | Sell |
379
-1,458
| -79% | -$2.44K | ﹤0.01% | 5995 |
|
|
2022
Q1 | $5K | Sell |
1,837
-8,737
| -83% | -$30.9K | ﹤0.01% | 5801 |
|
|
2021
Q4 | $64K | Buy |
10,574
+5,419
| +105% | +$32.3K | ﹤0.01% | 4951 |
|
|
2021
Q3 | $34K | Buy |
5,155
+1,272
| +33% | +$7.99K | ﹤0.01% | 4960 |
|
|
2021
Q2 | $26K | Sell |
3,883
-17,990
| -82% | -$153K | ﹤0.01% | 5153 |
|
|
2021
Q1 | $203K | Sell |
21,873
-2,055
| -9% | -$25K | ﹤0.01% | 4000 |
|
|
2020
Q4 | $430K | Buy |
23,928
+23,916
| +199,300% | +$420K | ﹤0.01% | 4332 |
|
|
2020
Q3 | $0 | Buy |
+12
| New | +$79 | ﹤0.01% | 7465 |
|
|
2018
Q1 | – | Sell |
-28
| Closed | -$1K | – | 7555 |
|
|
2017
Q4 | $1K | Hold |
28
| – | – | ﹤0.01% | 7461 |
|
|
2017
Q3 | $1K | Buy |
+28
| New | +$1.75K | ﹤0.01% | 7109 |
|
|
2017
Q2 | – | Sell |
-3
| Closed | -$193 | – | 7348 |
|
|
2017
Q1 | $0 | Sell |
3
-392
| -99% | -$53.2K | ﹤0.01% | 7194 |
|
|
2016
Q4 | $60K | Buy |
395
+338
| +593% | +$78.9K | ﹤0.01% | 6055 |
|
|
2016
Q3 | $17K | Buy |
57
+34
| +148% | +$12.4K | ﹤0.01% | 6280 |
|
|
2016
Q2 | $8K | Sell |
23
-289
| -93% | -$99.5K | ﹤0.01% | 6624 |
|
|
2016
Q1 | $104K | Buy |
312
+260
| +500% | +$88.5K | ﹤0.01% | 5639 |
|
|
2015
Q4 | $20K | Buy |
52
+29
| +126% | +$11.4K | ﹤0.01% | 6481 |
|
|
2015
Q3 | $10K | Sell |
23
-5
| -18% | -$2.62K | ﹤0.01% | 6416 |
|
|
2015
Q2 | $20K | Buy |
28
+5
| +22% | +$3.55K | ﹤0.01% | 6093 |
|
|
2015
Q1 | $11K | Hold |
23
| – | – | ﹤0.01% | 6413 |
|
|
2014
Q4 | $7K | Sell |
23
-2
| -8% | -$647 | ﹤0.01% | 6580 |
|
|
2014
Q3 | $9K | Sell |
25
-14
| -36% | -$4.19K | ﹤0.01% | 6310 |
|
|
2014
Q2 | $10K | Buy |
39
+13
| +50% | +$4.16K | ﹤0.01% | 6160 |
|
|
2014
Q1 | $11K | Sell |
26
-52
| -67% | -$22.5K | ﹤0.01% | 6293 |
|
|
2013
Q4 | $33K | Buy |
78
+55
| +239% | +$24.5K | ﹤0.01% | 5927 |
|
|
2013
Q3 | $12K | Hold |
23
| – | – | ﹤0.01% | 6134 |
|
|
2013
Q2 | $12K | Buy |
+23
| New | +$10.4K | ﹤0.01% | 6023 |
|
Other funds holding CRDF
VCM
LCM
P
ACA
FLPIM
Citigroup's CRDF Position: Q1 2026 in Review
Citigroup increased its Cardiff Oncology (CRDF) stake by 2,770% in Q1 2026, buying an estimated $79.8K and bringing the position to 40,266 shares worth $65.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4428.
Citigroup first reported a position in CRDF in Q2 2013 and has held it in 37 quarters since. The position peaked at $1.07M in Q1 2023. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.
- Citigroup held 40,266 shares of Cardiff Oncology worth $65.2K as of Q1 2026.
- Citigroup bought 38,863 Cardiff Oncology shares in Q1 2026, an estimated $79.8K.
- Cardiff Oncology made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4428 holding.
- Citigroup first reported a position in Cardiff Oncology in Q2 2013 and has held it in 37 quarters since.
- Citigroup's Cardiff Oncology position peaked at $1.07M in Q1 2023.
- 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.